Literature DB >> 8448634

The 'side effects' of rheumatoid arthritis: joint destruction, disability and early mortality.

T Pincus1, L F Callahan.   

Abstract

Most patients with RA experience disease progression over periods longer than 5 years, characterized by radiographic joint destruction, declines in functional capacity to perform activities of daily living, frequent work disability, high levels of co-morbidities, and death earlier than expected. These long-term consequences of RA may be viewed as 'side effects' of disease, which must be balanced against possible side effects of drugs in planning treatments of patients with RA. Aggressive approaches, which may include acceptance of mild and even moderate side effects of drugs, may be appropriate in efforts to prevent 'side effects' of RA.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8448634

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  18 in total

1.  Differences in activity limitation, pain intensity, and global health in patients with rheumatoid arthritis in Sweden and the USA: a 5-year follow-up.

Authors:  M Björk; L Trupin; I Thyberg; P Katz; E Yelin
Journal:  Scand J Rheumatol       Date:  2011-09-21       Impact factor: 3.641

2.  Economic evaluation in rheumatology: a necessity for clinical studies.

Authors:  B Griffiths; P Emery; R Akehurst
Journal:  Ann Rheum Dis       Date:  1995-11       Impact factor: 19.103

3.  Value of the time trade off method for measuring utilities in patients with rheumatoid arthritis.

Authors:  G J Tijhuis; S J Jansen; A M Stiggelbout; A H Zwinderman; J M Hazes; T P Vliet Vlieland
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

4.  Measuring utilities by the time trade-off method in Tunisian rheumatoid arthritis patients.

Authors:  Ismail Bejia; Kamel Ben Salem; Mongi Touzi; Naceur Bergaoui
Journal:  Clin Rheumatol       Date:  2005-05-18       Impact factor: 2.980

Review 5.  The underestimated long term medical and economic consequences of rheumatoid arthritis.

Authors:  T Pincus
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 6.  An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.

Authors:  Nick J Bansback; Dean A Regier; Roberta Ara; Alan Brennan; Kamran Shojania; John M Esdaile; Aslam H Anis; Carlo A Marra
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison.

Authors:  B Combe; C Codreanu; U Fiocco; M Gaubitz; P P Geusens; T K Kvien; K Pavelka; P N Sambrook; J S Smolen; J Wajdula; S Fatenejad
Journal:  Ann Rheum Dis       Date:  2006-04-10       Impact factor: 19.103

8.  Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities.

Authors:  Y Yazici; T Sokka; H Kautiainen; C Swearingen; I Kulman; T Pincus
Journal:  Ann Rheum Dis       Date:  2004-06-18       Impact factor: 19.103

Review 9.  Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health States.

Authors:  Nick Bansback; Roberta Ara; Jonathan Karnon; Aslam Anis
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 10.  Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs.

Authors:  Tuulikki Sokka; Minja Envalds; Theodore Pincus
Journal:  Mod Rheumatol       Date:  2008-04-25       Impact factor: 3.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.